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Both lung disease and elevation of blood glucose are associated
with increased glucose concentration (from 0.4 to ∼4.0 mM) in
the airway surface liquid (ASL). This perturbation of ASL glucose
makes the airway more susceptible to infection by respiratory
pathogens. ASL is minute (∼1 μl/cm2) and the measurement
of glucose concentration in the small volume ASL is extremely
difficult. Therefore, we sought to develop a fluorescent biosensor
with sufficient sensitivity to determine glucose concentrations
in ASL in situ. We coupled a range of environmentally
sensitive fluorophores to mutated forms of a glucose/galactose-
binding protein (GBP) including H152C and H152C/A213R and
determined their equilibrium binding properties. Of these, GBP
H152C/A213R–BADAN (Kd 0.86 +− 0.01 mM, Fmax/F0 3.6) was
optimal for glucose sensing and in ASL increased fluorescence
when basolateral glucose concentration was raised from 1 to
20 mM. Moreover, interpolation of the data showed that the
glucose concentration in ASL was increased, with results similar
to that using glucose oxidase analysis. The fluorescence of
GBP H152C/A213R–BADAN in native ASL from human airway
epithelial cultures in situ was significantly increased over time
when basolateral glucose was increased from 5 to 20 mM. Overall
our data indicate that this GBP is a useful tool to monitor glucose
homoeostasis in the lung.
Key words: airway epithelial cell, airway surface liquid, BADAN,
glucose, glucose-binding protein.
INTRODUCTION
The respiratory tract is covered by a thin layer of fluid that lines the
luminal surface of the epithelium [airway surface liquid (ASL)],
which is important for lung defence against infection. In the upper
airway, glucose concentrations are normally ∼0.4 mM, 12.5 times
lower than in plasma at ∼5 mM, which serves to deprive bacteria
of a potential food source and thus limits bacterial growth [1–
4]. There is accumulating evidence that glucose concentrations
are raised in patients (up to 4 mM) during airway inflammation
(e.g. in respiratory disease), when blood glucose levels are
increased (e.g. in diabetes mellitus) and, more potently, when
both are present. Similar changes can also be detected in the
ASL of in vitro models of airway epithelium in response to
basolateral hyperglycaemia and pro-inflammatory stimuli [5–7].
The increase in ASL glucose concentrations makes the airways
more susceptible to infection from pathogens such as methicillin-
resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Measurement of glucose concentrations in the airways and
distal lungs of patients, in in vivo models of airways disease
and in vitro models of airway epithelium is difficult because
of limited accessibility, the thinness of the ASL (∼7 μm)
and low concentrations of glucose obtained when dilution
techniques are used (e.g. brochoalveolar lavage and exhaled
breath condensate). Standard techniques such as glucose oxidase
analysis or HPLC are concentration-limited and time-consuming
respectively. Moreover, neither technique enables real-time
dynamic changes in ASL glucose concentration in response to
hyperglycaemic/pro-inflammatory challenge to be measured. The
development of biosensors to measure glucose in the airway
in vitro and in vivo will be a useful tool to better understand
ASL glucose homoeostasis, how it is changed with inflammation
and hyperglycaemia and how it modifies the innate immunity in
the ASL.
Recently, the development of molecular glucose sensors for less
invasive continuous monitoring of plasma glucose in patients has
received significant interest in the field of diabetes research. One
of these biosensors employs glucose/galactose-binding protein
(GBP) which alters its conformation when glucose binds. This
protein has been covalently linked to environmentally sensitive
fluorophores which allow glucose binding to be detected as a
change in fluorescence [8,9]. Native bacterial GBP has a very low
dissociation constant (Kd 2 μM) [8] which is not appropriate for
ASL glucose measurement. However, in the present study we have
used mutated forms of the GBP with altered binding constants
(GBP H152C and GBP H152C/A213R), covalently bound to
environmentally sensitive fluorophores. The molecular glucose
sensors were characterized in terms of affinity and dynamic
range, and their potential for measurement of glucose in ASL
in situ was assessed.
EXPERIMENTAL
Materials
Escherichia coli XL10-Gold and BL21(DE3) Gold cells were
purchased from Stratagene. EZ-Run protein ladder was purchased
Abbreviations: ASL, airway surface liquid; EMEM, Eagle’s minimal essential medium; GBP, glucose/galactose-binding protein; HBEC, human bronchial
epithelial cell; Ni-NTA, Ni2+-nitrilotriacetate; PSS, physiological salt solution; TCEP, tris-(2-carboxyethyl)phosphine.
1 To whom correspondence should be addressed (email d.baines@sgul.ac.uk).
c© The Authors Journal compilation c© 2014 Biochemical Society
214 N. Helassa and others
Table 1 Summary of the biophysical characteristics of GBP-labelled mutants
The asterisks (*) indicate that fluorescence was decreased upon glucose binding.
Protein Fluorophore λexc/λem K d (mM) n R2 F max/F 0
GBP H152C IANBD 470/535 0.18 +− 0.01 1.8 +− 0.1 0.98 3.6
Blue Oxazine 637/666 0.22 +− 0.03 0.7 +− 0.1 0.57 1.3
Nile Blue 625/670 0.19 +− 0.02 0.8 +− 0.1 0.51 1.4
Chromis 678 677/701 0.046 +− 0.002 1.4 +− 0.1 0.93 1.4
mero53 594/618 0.65 +− 0.01 1.8 +− 0.1 0.93 1.8*
mero87 591/616 0.68 +− 0.02 1.1 +− 0.1 0.90 1.8*
GBP H152C/A213R BADAN 387/535 0.86 +− 0.01 1.2 +− 0.1 0.99 3.5
Blue Oxazine 637/666 4.6 +− 0.3 1.1 +− 0.1 0.80 1.3
Nile Blue 625/670 11.4 +− 0.5 0.8 +− 0.1 0.93 1.7
Chromis 678 677/701 15.2 +− 0.3 1.1 +− 0.1 0.98 1.4
mero62 586/608 1.4 +− 0.1 1.2 +− 0.1 0.97 1.7
from Fisher Bioreagents and Ni2+-nitrilotriacetate (Ni-NTA) resin
from Qiagen. IANBD, Click-iT® Protein Reaction Buffer kit and
iodoacetamide alkyne were obtained from Life Technologies.
BADAN, oxazine derivatives (Blue Oxazine, Red Oxazine
and Nile Blue) and Chromis dyes (Chromis 630 and 678)
were purchased from Eurogentec, Chromeon and Cyanagen,
respectively. The merocyanine dyes (Mero 53, 62 and 87) were
synthesized as previously described [10–12]. Texas Red–dextran
was obtained from Life Technologies.
Expression and purification of GBP proteins
The expression vectors pET303-GBP H152C and pET303-GBP
H152C/A213R were used for the production of the GBP mutants
[8]. GBP proteins were overexpressed in E. coli BL21(DE3) Gold.
Cells were grown at 37 ◦C and expression was induced overnight
at 20 ◦C in the presence of 0.5 mM IPTG. Cells were pelleted by
centrifugation and processed as previously described [9]. Briefly,
cells were resuspended in 50 mM NaH2PO4, 300 mM NaCl,
10 mM imidazole and 5 mM tris-(2-carboxyethyl)phosphine
(TCEP), pH 8, supplemented with Complete EDTA-free protease
inhibitor cocktail (Roche). The suspension was incubated on ice
with 1 mg·ml− 1 lysozyme for 30 min before lysis by sonication
(VibraCell, Jencons PLS), clarified by centrifugation and purified
by Ni-chromatography on an ¨AKTA Purifier system (GE
Healthcare) at 4 ◦C. The 5 ml Ni-NTA column was equilibrated
with 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole and
5 mM TCEP, pH 8. The purified protein was eluted in buffer
containing 300 mM imidazole and stored at − 80 ◦C. Purity of
the eluted fractions was determined by SDS/PAGE.
Measurement of protein concentration
Protein concentration was determined using a Nanodrop 1000
spectrophotometer (Thermo Scientific) with a molar absorption
coefficient (εo) of 37,930 M− 1·cm− 1, calculated from the amino
acid composition [13].
Protein labelling using thiol-reactive dyes (IANBD, BADAN,
mero53, mero62 and mero87)
For labelling with UV-excitable fluorophores, GBP proteins
(100 μM) were incubated in the presence of 10-fold excess of dye
(IANBD or BADAN) overnight at 4 ◦C in PBS and 5 mM TCEP,
pH 7.4 [14]. The excess of dye was removed by gel filtration using
a PD-10 column (GE Healthcare). For labelling with merocyanine
dyes, 100 μM of protein were mixed with 5-fold excess of dye
for 2 h at room temperature in PBS, pH 7.4. The excess of dye
was removed by extensive dialysis in PBS, pH 7.4 at 4 ◦C (Slide-
a-Lyser 10 kDa cut-off, Pierce).
Protein labelling using click chemistry for oxazine derivatives
(Blue Oxazine, Red Oxazine, Nile Blue) and chromis dyes (Chromis
630, Chromis 678)
First, GBP-alkyne was obtained by incubating 100 μM GBP with
10-fold excess of iodoacetamide alkyne in PBS and 2.5 mM
TCEP, pH 7.4, for 2 h at room temperature. The excess of
iodoacetamide alkyne was removed by extensive dialysis in PBS,
pH 7.4, at 4 ◦C (Slide-a-Lyser 10 kDa cut-off, Pierce). The second
step of the process consisted of labelling the GBP-alkyne with
the dye azide using the Click-iT® Protein Reaction Buffer kit
following the manufacturer’s recommendations. Briefly, 40 μM
GBP-alkyne was incubated with 2.5-fold excess of dye in 100 μM
reaction buffer containing 25 μl of copper sulfate reagent and
25 μl of kit additive 1, for 1 h at room temperature (V t = 500 μl).
The excess of dye was removed by extensive dialysis in PBS,
pH 7.4, at 4 ◦C (Slide-a-Lyser 10 kDa cut-off, Pierce).
Equilibrium glucose binding
Equilibrium glucose-binding curves were obtained by continuous
titration followed by corrections for dilution and photobleaching.
To determine the fluorescence dynamic range (Fmax/F0), the co-
operativity (n) and the dissociation constant (Kd) of the labelled
GBP proteins, glucose affinity assays were performed using an
automated syringe pump (ALADDIN 1000, WPI). Labelled GBP
proteins (40–100 nM) were titrated continuously with D-glucose
at 10–20 μl/min flow rate in a stirred 3 ml cuvette, in PBS,
pH 7.4. Fluorescence was measured at fluorophore excitation and
emission wavelength peaks (Table 1) at 20 ◦C on a Fluorolog3
spectrofluorimeter (Horiba Scientific). Data are expressed as the
means +− S.E.M. of triplicates. The fluorescence changes were
normalized and fitted to the Hill equation Y = Bmax×Xn/(Kdn + Xn)
using Prism GraphPad 6 software.
Fluorescence stability at 37 ◦C of GBP H152C/A213R–
BADAN (100 nM) was monitored over 7 h (λexc 387 nm and λem
535 nm) under physiological ionic strength (PBS, pH 7.4).
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Cell culture and ASL glucose measurement
Calu-3 cells
The human adenocarcinoma-derived cell line, Calu-3 [15], was
grown in Eagle’s minimal essential medium (EMEM) plus
10%FBS, 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml
streptomycin, and 1% non-essential amino acids (Sigma) and
incubated in humidified air containing 5% CO2 at 37 ◦C. Calu-3
cells were seeded on to clear Costar Transwell® inserts (0.45-
μm pore size) at 250000 cells/cm2 to form confluent polarized
monolayers, as previously described [16]. Experiments were
carried out 10–14 days post-seeding. Calu-3 cells were bathed
with 100 μl of glucose-free physiological salt solution (PSS)
(117 mM NaCl, 25 mM NaHCO3, 4.7 mM KCl, 1.2 mM MgSO4,
1.2 mM KH2PO4 and 2.5 mM CaCl2) on the apical surface and
1 ml of PSS on the basolateral side supplemented with 1, 2, 5, 10,
15 or 20 mM glucose, in a 95% O2/5% CO2 gassed incubator
at 37 ◦C. The ASL was collected after 1 h or 24 h. GBP–BADAN
(2 μl) was added to 48 μl of ASL and fluorescence measured on a
Fluorolog3 spectrofluorimeter (Horiba Scientific) at λexc 387 nm
and λem 535 nm. The remaining 50 μl of ASL was analysed using
glucose oxidase (Glucox).
Primary human bronchial epithelial cells
Primary human bronchial epithelial cells (HBECs) were obtained
from endobronchial brushings or extracted from explanted lungs
and cultured as previously described [17–19]. HBECs were
obtained in accordance with approval from the relevant ethics
committees: The University of North Carolina at Chapel Hill
Biomedical Institutional Review Board (protocol #03-1396).
Cells were transferred on to transwell permeable supports and
grown at air–liquid interface to form confluent monolayers.
Cells were studied 3–5 weeks post-seeding. For ASL glucose
studies, cells were transferred into Hepes-buffered PSS (24 mM
Hepes, 101 mM NaCl, 12 mM NaHCO3, 1.2 mM MgCl2, 1.2 mM
CaCl2·2H2O and 5.2 mM KCl) and the apical surface washed with
100 μl. PSS (20 μl) containing 0.1 mg/ml Texas Red–dextran
10000 Mr (Life Technologies) and 2 μl of a 50 μM solution
of GBP–BADAN were added to the apical surface and the
fluorescence emission of Texas Red and BADAN was analysed
from five different areas of the transwell surface using a Infinite
M1000 plate reader (Tecan). To initiate the experiment, 5 mM D-
glucose, 10 mM D-glucose, 20 mM D-glucose, 5 mM D-glucose
plus 5 mM L-glucose (osmotic control for 10 mM D-glucose),
or 5 mM D-glucose plus 15 mM L-glucose (osmotic control for
20 mM D-glucose), was added to the basolateral chamber and
fluorescent readings of the apical surface taken hourly. Data
were analysed as the ratio of GBP–BADAN/Texas Red–dextran
fluorescence (to correct for changes in ASL fluid volume).
Statistical methods
Groups were compared using ANOVA with Tukey’s post-hoc test.
Results are presented as means +− S.E.M., unless otherwise stated.
RESULTS
Equilibrium glucose binding to GBP H152C and H152C/A213R
GBP proteins were highly purified on a single-step affinity
chromatography column (Figure S1), allowing accurate
concentration measurements by spectrophotometry. One litre of
culture yielded in 200–250 mg of purified protein.
Glucose equilibrium binding for labelled GBP H152C and
H152C/A213R showed that using UV-excitable environmentally
sensitive dyes such as BADAN and IANBD offered the highest
fluorescence dynamic range (Fmax/F0) ranging from 2.7 to 3.6
(Table 1). GBP labelled with long-wavelength excitable dyes
showed a maximum fluorescence change upon glucose binding of
80% for GBP H152C coupled to merocyanines. The dissociation
constant (Kd) for GBP H152C and GBP H152C/A213R
ranged from 0.046 +− 0.002 mM to 0.68 +− 0.02 mM and from
0.86 +− 0.01 mM to 15.2 +− 0.3 mM, respectively (Figure 1 and
Table 1). For most labelled glucose-binding proteins, glucose
binding did not occur with co-operativity as determined by
analysis of the Hill coefficient (n). All the parameters obtained
from the glucose titration curves are summarized in Table 1. GBP
H152C and GBP H152C/A213R labelled with Red Oxazine and
Chromis 630 did not show a significant fluorescence change upon
glucose binding (results not shown).
Specificity of GBP H152C/A213R–BADAN (GBP–BADAN) for
D-glucose
The specificity of glucose induced fluorescence of GBP–BADAN
was analysed in PSS by comparing fluorescence in the presence of
D-glucose, its isomer L-glucose and D-fructose. Fluorescence did
not change with increasing D-fructose or L-glucose concentration
but exhibited a similar dose response to D-glucose as described
above (Figure 2A). There was a significant difference in the mean
values between 0.01 and 0 mM D-glucose (i.e. in the presence of L-
glucose) (P = 4.6944×10− 5, n = 3). This indicated that the limit
of detection was below 0.01 mM. However, we did not explore this
further because values below 0.01 mM were not relevant to our
study system. This was also the case for glucose concentrations
above 50 mM. The calculated value for precision (3.3×S.D./slope
for the linear part of the graph shown in Figure 1) was 0.27 mM.
Comparison of GBP–BADAN fluorescence with glucose oxidase
measurement of glucose concentration
Glucose oxidase analysis showed similar D-glucose specificity,
with mM values obtained for increasing concentrations of L-
glucose and D-fructose being unchanged from 0 (Figure 2B).
Interestingly, GBP–BADAN exhibited changes in fluorescence
at low concentrations of D-glucose (from 0.01 mM; Figure 2A).
Changes in low glucose concentrations were less discernable by
glucose oxidase analysis. Furthermore, changes in fluorescence
could be detected at concentrations up to 50 mM where
no accurate and repeatable readings could be determined at
this concentration by glucose oxidase analysis calibrated for
standard glucose measurement (glucose oxidase data not shown).
Therefore, GBP–BADAN appears to be a more sensitive probe
than glucose oxidase and can measure glucose over a broader
range of concentration.
GBP–BADAN to measure hyperglycaemia-induced changes in
Calu-3 ASL glucose concentration
Serous and mucous cells of the airway submucosal glands
make a significant contribution to the volume, composition and
consistency of the ASL in vivo. Calu-3 cells, a heterogenous
cell line derived from human submucosal glands, secrete a
protein-rich fluid containing mucins, antimicrobials and enzymes
[15,20,21]. Calu-3 monolayers were used to determine whether
the protein-rich ASL would affect the stability of GBP–BADAN
to accurately measure glucose content. Fluid was added to
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Figure 1 Equilibrium glucose titrations for fluorescently labelled GBP H152C and GBP H152C/A213R
Equilibrium glucose titrations for GBP H152C and GBP H152C/A213R, labelled with UV-excitable dyes (A), oxazine derivatives (B), Chromis 678 (C) and Merocyanine dyes (D). Titrations were
carried out in at least triplicates and the curves represent the means +− S.E.M. Data were fitted to the Hill equation using GraphPad Prism 6.0 and the fitted parameters are shown in Table 1.
the apical surface and removed after 1 and 24 h, and glucose
concentrations measured by glucose oxidase and GBP–BADAN
fluorescence. Hyperglycaemia was mimicked by increasing the D-
glucose concentration of the basolateral fluid (from 1 to 20 mM),
as previously described [6].
GBP–BADAN fluorescence in ASL increased significantly
when basolateral D-glucose was elevated from 1 to 5 mM
and above (P < 0.05, n = 4) with maximal values occurring
when basolateral glucose was 15–20 mM (P < 0.01, n = 4). ASL
glucose concentrations were higher in samples obtained after
24 h compared with 1 h after elevation of basolateral D-glucose
(Figure 3A).
A similar pattern was observed when glucose concentration
in the samples of ASL was analysed by glucose oxidase
method. At 1 h, glucose concentration in ASL was very
low (0.007 +− 0.002 mM) and at the limit of detection when
basolateral D-glucose was 1–2 mM but significantly increased
when basolateral glucose was raised to 5 mM (0.3 +− 0.06 mM
in ASL; P < 0.01, n = 4) and was highest when basolateral D-
glucose was increased to 15 mM (1.1 +− 0.3 mM; P < 0.01, n = 4).
ASL glucose further increased after 24 h rising to 0.6 +− 0.17
and 5.0 +− 1.2 mM when basolateral D-glucose was 5 and 15 mM,
respectively (Figure 3B). Importantly, ASL glucose concentration
remained lower than basolateral glucose at any concentration
tested.
Airway epithelial monolayers maintained their transepithelial
resistance when glucose in the basolateral chamber was replaced
with fructose, as previously reported [22]. As fructose did not bind
to GBP–BADAN, ASL from cells grown in basolateral fructose
was used to obtain ASL in which glucose was not present and
correct for background fluorescence. Then, using the standard
curve (Figure 2C), ASL glucose concentration can be determined.
Importantly, the interpolated ASL glucose concentrations were
similar to those determined by glucose oxidase analysis at
0.2 +− 0.1 and 0.8 +− 0.4 mM when basolateral D-glucose was
5 mM and 2.0 +− 0.8 and 4.8 +− 1.1 mM when basolateral D-
glucose was 15 mM at 1 and 24 h respectively (Figure 3C). These
data indicate that GBP–BADAN fluorescence can be used to
accurately measure ASL glucose at similar sensitivity to glucose
oxidase analysis.
GBP–BADAN to measure dynamic changes in HBEC ASL glucose
concentration in response to hyperglycaemic challenge in situ
Having shown that GBP–BADAN could be used to measure
changes in ASL glucose concentrations collected from Calu-
3 monolayers, we investigated whether the GBP assay could
be used to detect dynamic changes in situ, in response to
elevated basolateral glucose, by applying GBP–BADAN directly
to the apical surface of primary HBECs. Applying even small
volumes of fluid to the apical surface of HBECs induces fluid
absorption [23]. Therefore, to control for the effect of ASL
volume changes on glucose concentration, we used Texas Red-
labelled dextran together with GBP–BADAN and calculated the
change in fluorescence of GBP–BADAN/Texas Red ratio. Using
this methodology, we found that fluorescence increased in the
ASL of all HBECs after 1 h and reached peak fluorescence
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Figure 2 Titration of BADAN-labelled GBP H152C/A213R (GBP–BADAN) with monosaccharides
Titration of BADAN-labelled GBP H152C/A213R (GBP–BADAN) (A) with D-glucose, L-glucose or D-fructose, in PSS compared with glucose oxidase analysis (B). Fluorescence intensity titration curve
for GBP–BADAN (D-glucose minus D-fructose) (C). This curve was used to interpolate data shown in Figure 3. Titrations were carried out in triplicate and the curves represent the means +− S.E.M.
Data were fitted to the Hill equation using GraphPad Prism 6.0. a.u., arbitrary unit (s).
after 3 h (Figure 4). Although no significant difference in GBP–
BADAN fluorescence was observed in the ASL of HBECs bathed
in 10 mM basolateral glucose compared with 5 mM control,
increasing basolateral glucose to 20 mM significantly enhanced
fluorescence after 2 h (P < 0.05, n = 4). The increase in GBP–
BADAN fluorescence was maintained throughout the 5 h time-
course and was also significantly greater than cells bathed in 5 mM
D-glucose plus 15 mM L-glucose (from 3 h onwards; P < 0.05,
n = 4), consistent with a glucose-induced change in fluorescence
rather than one induced by a difference in osmotic gradients.
The fluorescence of GBP–BADAN was monitored over 7 h
at 37 ◦C and no significant change in fluorescence was observed
indicating that the labelled protein was stable over this time course
(Figure S2).
DISCUSSION
The world burden of diabetes is increasing both as an independent
disease and as co-morbidity with other chronic conditions. In the
lung, evidence is accumulating that hyperglycaemia associated
with Type 1 and Type 2 diabetes results in increased glucose
concentration in the ASL which promotes infection, particularly
when associated with underlying respiratory disease [1,5,6,24–
27]. However, measurement of real-time changes of ASL glucose
in vitro and in vivo has not previously been possible.
Evidence indicates that glucose concentrations in the ASL
range from approximately 0.4 to 4.0 mM in vivo and in vitro
[1,6,7,24]. In order to efficiently monitor glucose concentrations
in ASL in vivo, the biosensors should have a Kd between 0.1
and 10 mM and a high fluorescence dynamic range upon glucose
binding. We initially disregarded GBP H152C (which contains
a mutation to enable covalent labelling of fluorophores via the
cysteine amino acid) because when it was bound to BADAN the Kd
was 2 μM, somewhat below our ideal range [8,28]. However, our
data showed that when bound to other fluorophores, particularly
IANBD, a shift in the Kd to higher, more useful, values in the
millimolar range could be achieved. Similar increases in Kd were
also observed when these fluorophores were attached to GBP
H152C/A213R. These data indicate that the molecular structure
of the fluorophore bound to these proteins can significantly modify
affinity for the ligand, consistent with the findings of others [9,29].
Unfortunately, linking the double mutant to IANBD increased
the Kd to ∼32 mM (results not shown), making it unlikely to
be suitable for ASL glucose measurement, although it gave
the next best dynamic range after BADAN. Interestingly, all
the longer wavelength fluorophores, which were designed for
in vivo imaging, were less sensitive to environmental changes
and had lower fluorescence dynamic ranges. These fluorophores
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Figure 3 Determination of glucose concentrations in ASL
Determination of glucose concentrations in ASL removed from Calu-3 monolayers grown at air–liquid interface in different basolateral glucose concentrations for 1 and 24 h measured by fluorescence
(A) and glucose oxidase analysis (B), using BADAN-labelled GBP H152C/A213R (GBP–BADAN). Glucose concentration calculated by interpolation of fluorescence intensity of GBP–BADAN (C),
using graph shown in Figure 2(c). Data represent the means +− S.E.M. Significantly different from 1 mM glucose: *P < 0.05, **P < 0.01, ***P < 0.001, n = 4.
were based on optimization of both environmental sensitivity and
brightness, as these factors together determine sensitivity in living
cells [30]. Of these dyes, GBP H152C/A213R–mero62 was the
most promising for further development with a Kd of 1.4 mM and
a fluorescence dynamic range of 1.7.
GBP H152C/A213R–BADAN (GBP–BADAN) gave the most
useful Kd (0.86 +− 0.01 mM) and the largest fluorescence dynamic
range (Fmax/F0 3.5) and exhibited clear specificity for D-glucose.
Moreover, we found that it was a better sensor over the
range of glucose concentrations required than using the glucose
oxidase method. This was in part due to technical limitations
of the sensing machine. That is, in order to obtain readings at
concentrations below 1 mM, the Glucox analyser has to be re-
calibrated differently from settings used to obtain blood glucose
readings (2–20 mM). This meant that glucose concentrations in
the higher range >10 mM did not give a consistent output value.
When measuring glucose in samples of ASL removed from the
surface of cells, GBP–BADAN and glucose oxidase analysis
showed similar changes with increasing basolateral glucose.
Glucose oxidase analysis gave absolute glucose concentrations
whereas we obtained fluorescence intensity for GBP–BADAN.
We utilized the finding that the presence of basolateral D-fructose
(which maintains cell survival) is not sensed by GBP–BADAN
to obtain background fluorescence readings for ASL with no
glucose. This enabled us to convert the mean fluorescence data
into glucose concentration (mM) by interpolation of the standard
curve. Glucose concentration values obtained by fluorescence
Figure 4 Dynamic changes in primary human bronchial ASL glucose
concentration in situ
Dynamic changes in primary human bronchial epithelial ASL glucose concentration in situ,
measured as fluorescence of BADAN-labelled GBP H152C/A213R in response to raised
basolateral glucose over time. Data are shown as means +− S.E.M. Significantly different from
all other columns at time point: *P < 0.05; significantly different from 5 mM D-glucose only:
#P < 0.05, n = 4.
and the glucose oxidase data were similar, providing support
for the use of GBP–BADAN to quantify glucose in ASL.
Most importantly, the data we gained from these experiments
showed that glucose concentration in ASL increased with raised
basolateral glucose but concentrations remained significantly
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lower in ASL, consistent with our previous findings in vitro and
in vivo [6,7,24].
Work by others has shown that highly technical glucose
sensor technology using ZnO-coated microelectrodes or a
phosphorescence sensing material [crystalline iridium(III)-
Zn(II) co-ordination polymers], which utilize glucose oxidase
production of H2O2 to quantify glucose, can be useful in
measuring glucose in small fluid volumes such as ASL and over
similar ranges of glucose (0.1–6 mM) [26,31,32]. However, the
benefit of a fluorescent molecular glucose sensor that is easy
to produce and can be used to rapidly measure real-time (and
reversible) changes in glucose concentration in ASL overlying
cells in situ is particularly attractive. In a unique experiment, we
used GBP–BADAN applied directly to the ASL of HBECs in
situ and showed that glucose concentration rises faster and to
higher levels over a time course of 5 h when basolateral glucose
concentration was increased from 5 to 20 mM. These data support
our model of glucose homoeostasis where raised basolateral
glucose concentration increases the driving force for glucose
diffusion into ASL. The resultant ASL glucose concentration
is the net balance between diffusion and glucose uptake by
the epithelial cells. Thus, if uptake remains the same, increased
diffusion would result in elevated ASL glucose [33,34].
These experiments now open the way for development of
fluorophore-labelled GBPs as biosensors, for use in vitro and
in vivo, to further understand how hyperglycaemia and respiratory
disease change ASL glucose concentration in the proximal
and distal lung. We now intend to use GBP–BADAN applied
directly to ASL of proximal and distal airway cells in vitro
to explore factors regulating glucose homoeostasis. In vivo, we
have previously used glucose oxidase sticks to detect glucose
in human nasal secretions. We have shown that changes in
glucose concentration in nasal secretions are representative of
the airway as a whole [24,35,36]. However, these sticks are
no longer available, colour change interpretation was subjective
and dynamic changes were difficult to measure. Therefore,
immobilization of GBP–BADAN and its incorporation into a
small fibre-optic probe (<1 mm diameter) for insertion into the
nasal cavity, could prove a more accurate and minimally invasive
biosensor for detection of glucose in nasal secretions [37]. During
our in vitro experiments we did not observe any changes in
transepithelial resistance which indicated GBP–BADAN toxicity,
but this will need to be tested further. Nevertheless, we hope such
tools will be helpful to find new ways to reduce glucose in ASL
and help combat respiratory infections.
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